Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

ARCA Biopharma Inc (ABIO) USD0.001

Sell:$3.11 Buy:$3.13 Change: $0.05 (1.64%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Change: $0.05 (1.64%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Change: $0.05 (1.64%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is focused on development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product includes Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) and Gencaro(bucindolol hydrochloride). rNAPc2 (AB201) is a treatment for diseases caused by ribonucleic acid (RNA), viruses, focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus. Gencaro(bucindolol hydrochloride) is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties for the treatment of atrial fibrillation (AF) in patients with heart failure. AF is the form of cardiac arrhythmia, a disruption of the heart’s normal rhythm or rate. The Company is conducting Phase II b clinical trial of rNAPc2 (AB201), ASPEN-COVID-19. It is also conducting Phase IIB/III clinical trial of Gencaro.

Contact details

10170 Church Ranch Way, Suite 100
United States
+1 (720) 9402200

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$43.52 million
Shares in issue:
14.41 million
United States
US dollar

Key personnel

  • Robert Conway
    Chairman of the Board
  • Michael Bristow
    President, Chief Executive Officer, Director
  • C. Jeffrey Dekker
    Chief Financial Officer, Principal Accounting Officer
  • Thomas Keuer
    Chief Operating Officer
  • Christopher Ozeroff
    Senior Vice President, General Counsel, Secretary
  • Christopher Graybill
    Vice President, Clinical Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.